Semaglutide vs Tirzepatide: Which Is Right for You?

Two medications dominate the conversation around GLP-1 weight loss treatment right now: semaglutide and tirzepatide. Both work. Both have strong clinical data behind them. But they are not the same drug, and choosing between them is not simply a matter of picking the newer one. This guide breaks down how each works, what the clinical trials actually showed, and what questions are worth discussing with a clinician before you decide.

How GLP-1 medications work

GLP-1 stands for glucagon-like peptide-1, a hormone your body produces naturally after eating. It signals the pancreas to release insulin, slows the rate at which food leaves your stomach, and — critically for weight management — communicates with the brain's appetite centers to reduce hunger. When you take a GLP-1 medication, you are essentially amplifying that hormonal signal on a sustained basis.

The result is a meaningful reduction in appetite and calorie intake, without the stimulant side effects of older weight loss drugs. Both semaglutide and tirzepatide work through this pathway. Where they differ is in how broadly they act — and that difference has real-world consequences.

What is semaglutide?

Semaglutide is a GLP-1 receptor agonist developed by Novo Nordisk. It binds to and activates GLP-1 receptors throughout the body, reducing appetite, slowing gastric emptying, and helping regulate blood sugar. It was originally approved under the brand name Ozempic for type 2 diabetes, then later approved at a higher dose as Wegovy specifically for chronic weight management.

In the STEP clinical trials, participants taking semaglutide at the 2.4 mg weekly dose lost an average of approximately 15% of their body weight over 68 weeks — a result that was considered a landmark in obesity medicine at the time. For most people, that translated to meaningful reductions in waist circumference, blood pressure, and markers of cardiovascular risk.

Semaglutide has been prescribed widely since 2021, which means there is substantial real-world data on how patients tolerate it over time. The most common side effects are gastrointestinal: nausea, constipation, and occasional vomiting, most often occurring during dose escalation and typically improving within four to eight weeks.

Compounded semaglutide — the form available through platforms like PureForty — uses the same active molecule at the same dosing schedule, formulated by FDA-registered compounding pharmacies. It is dispensed as a weekly subcutaneous injection.

What is tirzepatide?

Tirzepatide, developed by Eli Lilly, takes the GLP-1 mechanism a step further. It is a dual agonist: it activates both the GLP-1 receptor and a second receptor called GIP (glucose-dependent insulinotropic polypeptide). GIP receptors are found in fat cells, muscle tissue, and the brain, and their activation appears to work synergistically with GLP-1 signaling to increase fat mobilization and energy expenditure beyond what GLP-1 activation alone produces.

Tirzepatide is marketed as Mounjaro for type 2 diabetes and Zepbound for weight management. In the SURMOUNT clinical trials, the highest dose produced average weight loss of around 20–22% of body weight — a result that had not been seen with any previous medication.

The side effect profile is similar to semaglutide: primarily gastrointestinal, primarily during dose escalation. Some studies have found slightly higher rates of injection site reactions with tirzepatide. Serious adverse events occurred somewhat more frequently in tirzepatide arms in certain comparative trials, though both drugs have strong overall safety records in clinical settings.

Semaglutide vs tirzepatide: head-to-head comparison

For years, the comparison between these two drugs was indirect — researchers drawing inferences from separate trials with different patient populations. That changed with the SURMOUNT-5 trial, a direct head-to-head randomized study published in the New England Journal of Medicine. The results were clear: participants on tirzepatide lost an average of 20.2% of their body weight over 72 weeks, compared to 13.7% for those on semaglutide. Tirzepatide participants were also significantly more likely to reach the 15%, 20%, and 25% weight loss thresholds.

The table below summarizes the key differences side by side.

On tolerability, the evidence is more nuanced. Both drugs cause similar rates of nausea overall. Semaglutide tends to be associated with slightly higher rates of constipation and GERD; tirzepatide with slightly higher rates of injection site reactions. Individual response varies enough that no generalizations reliably predict how a specific person will experience either drug. Some patients who struggled with nausea on semaglutide report tolerating tirzepatide well, and vice versa.

Which should you choose?

There is no universal answer, but there are useful guiding questions.

Consider semaglutide if:

• You want to start with the more established option, which has a longer real-world track record.
• Cost is a primary factor — semaglutide starts at $50/mo less than tirzepatide at PureForty.
• Your weight loss goal is meaningful but moderate (10–15% of body weight may achieve your health targets).
• You or your clinician want a more conservative starting point and the option to escalate to tirzepatide later if needed.

Consider tirzepatide if:

• Clinical trial data on efficacy is your primary decision driver — tirzepatide has consistently outperformed semaglutide in head-to-head comparisons.
• You have a higher starting BMI and are targeting more significant weight reduction.
• You have previously tried a GLP-1 medication and did not achieve the results you were hoping for.
• Your clinician, after reviewing your health history, recommends it as the more appropriate fit.

It is also worth being honest about one practical reality: the difference in efficacy is statistically significant and clinically meaningful, but a patient losing 13% of their body weight on semaglutide has still achieved a result that reduces cardiovascular risk, improves metabolic markers, and changes how they move through the world. Better on average does not mean right for every individual.

What neither medication can do is substitute for a clinician's judgment. Your weight loss history, current medications, kidney function, cardiovascular history, and personal goals all belong in that conversation — not just a comparison table.

How PureForty prescribes both

PureForty offers compounded semaglutide and compounded tirzepatide through a straightforward online process. You complete a medical intake, a licensed clinician reviews your information and determines whether you qualify, and if prescribed, your medication ships directly to your door from an FDA-registered compounding pharmacy.

There are no subscriptions. You pay per treatment cycle — one month, three months, or six months — and stop or switch whenever your plan changes. If you start on semaglutide and want to discuss switching to tirzepatide after your first cycle, that conversation happens with your clinician through your PureForty account.

Pricing is transparent. Compounded semaglutide starts at $149/mo on the six-month plan, and compounded tirzepatide starts at $199/mo. Both include provider consultation, the medication, and free shipping — no hidden fees, no separate consultation charges.

If you are still weighing your options, the weight loss medication page covers the clinical details of both drugs in more depth, and the compounded GLP-1 FAQ addresses the most common questions about compounded GLP-1 medications, including what compounding means and how it differs from brand-name products.